| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aromatase Inhibitors | 97 | 2021 | 519 | 14.610 |
Why?
|
| Triazoles | 61 | 2017 | 904 | 9.240 |
Why?
|
| Nitriles | 58 | 2017 | 980 | 9.040 |
Why?
|
| Breast Neoplasms | 196 | 2024 | 21207 | 6.700 |
Why?
|
| Androstadienes | 32 | 2024 | 348 | 5.960 |
Why?
|
| Tamoxifen | 51 | 2016 | 966 | 5.010 |
Why?
|
| Antineoplastic Agents, Hormonal | 47 | 2021 | 1536 | 4.840 |
Why?
|
| Neoplasms, Hormone-Dependent | 25 | 2014 | 410 | 4.470 |
Why?
|
| Chemotherapy, Adjuvant | 61 | 2024 | 3556 | 3.120 |
Why?
|
| Postmenopause | 60 | 2024 | 2518 | 2.740 |
Why?
|
| Antineoplastic Agents | 46 | 2017 | 13677 | 2.160 |
Why?
|
| Selective Estrogen Receptor Modulators | 12 | 2017 | 131 | 1.950 |
Why?
|
| Quinazolines | 9 | 2016 | 1373 | 1.730 |
Why?
|
| Receptors, Estrogen | 32 | 2024 | 2253 | 1.720 |
Why?
|
| Enzyme Inhibitors | 19 | 2008 | 3728 | 1.680 |
Why?
|
| Disease-Free Survival | 40 | 2024 | 6847 | 1.520 |
Why?
|
| Receptor, erbB-2 | 17 | 2016 | 2603 | 1.430 |
Why?
|
| Receptors, Progesterone | 17 | 2024 | 1160 | 1.330 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 40 | 2021 | 11878 | 1.220 |
Why?
|
| Androstenedione | 13 | 2009 | 132 | 1.140 |
Why?
|
| Uterus | 5 | 2011 | 663 | 1.110 |
Why?
|
| Anticarcinogenic Agents | 7 | 2012 | 251 | 1.090 |
Why?
|
| Bone Density | 14 | 2014 | 3573 | 1.070 |
Why?
|
| Estrogens | 18 | 2020 | 1536 | 1.040 |
Why?
|
| National Health Programs | 3 | 2013 | 442 | 1.010 |
Why?
|
| Health Services Accessibility | 9 | 2018 | 5520 | 0.970 |
Why?
|
| Neoplasm Recurrence, Local | 22 | 2021 | 9419 | 0.930 |
Why?
|
| Toremifene | 3 | 2009 | 24 | 0.890 |
Why?
|
| Pregnancy Complications, Neoplastic | 2 | 2017 | 260 | 0.880 |
Why?
|
| Breast | 11 | 2021 | 1976 | 0.880 |
Why?
|
| Female | 225 | 2024 | 397187 | 0.850 |
Why?
|
| Neoplasms | 16 | 2020 | 22371 | 0.820 |
Why?
|
| Clinical Trials as Topic | 25 | 2018 | 8052 | 0.770 |
Why?
|
| Health Planning | 2 | 2013 | 233 | 0.770 |
Why?
|
| Uterine Cervical Neoplasms | 4 | 2018 | 2043 | 0.710 |
Why?
|
| Latin America | 6 | 2017 | 416 | 0.710 |
Why?
|
| Drug Administration Schedule | 20 | 2016 | 4861 | 0.690 |
Why?
|
| Papillomavirus Vaccines | 2 | 2017 | 497 | 0.690 |
Why?
|
| Mammography | 14 | 2021 | 2433 | 0.680 |
Why?
|
| Mexico | 7 | 2020 | 769 | 0.680 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 4 | 2018 | 319 | 0.670 |
Why?
|
| Humans | 263 | 2024 | 768171 | 0.660 |
Why?
|
| Imidazoles | 4 | 2011 | 1169 | 0.650 |
Why?
|
| Early Detection of Cancer | 7 | 2021 | 3239 | 0.630 |
Why?
|
| Carcinoma, Ductal, Breast | 5 | 2018 | 1099 | 0.630 |
Why?
|
| Osteoporosis | 5 | 2014 | 1605 | 0.630 |
Why?
|
| Double-Blind Method | 23 | 2016 | 12466 | 0.610 |
Why?
|
| Placebos | 13 | 2012 | 1667 | 0.610 |
Why?
|
| Middle Aged | 120 | 2024 | 223487 | 0.580 |
Why?
|
| Premenopause | 7 | 2017 | 1039 | 0.580 |
Why?
|
| Vasomotor System | 2 | 2016 | 208 | 0.580 |
Why?
|
| Aged | 98 | 2024 | 171502 | 0.560 |
Why?
|
| Lipids | 6 | 2012 | 3345 | 0.550 |
Why?
|
| Carcinoma, Lobular | 2 | 2017 | 480 | 0.550 |
Why?
|
| Developed Countries | 2 | 2016 | 451 | 0.540 |
Why?
|
| Receptors, Interleukin | 3 | 2016 | 243 | 0.530 |
Why?
|
| WT1 Proteins | 1 | 2017 | 183 | 0.520 |
Why?
|
| Treatment Outcome | 49 | 2021 | 65379 | 0.520 |
Why?
|
| Developing Countries | 3 | 2018 | 2910 | 0.510 |
Why?
|
| Choristoma | 1 | 2017 | 205 | 0.500 |
Why?
|
| Diphosphonates | 4 | 2017 | 634 | 0.500 |
Why?
|
| Neoplasm Metastasis | 15 | 2018 | 4913 | 0.500 |
Why?
|
| Quality of Life | 25 | 2020 | 13490 | 0.490 |
Why?
|
| Estrogen Antagonists | 5 | 2009 | 151 | 0.480 |
Why?
|
| Musculoskeletal System | 2 | 2014 | 188 | 0.480 |
Why?
|
| Neoplasm Staging | 20 | 2021 | 11244 | 0.480 |
Why?
|
| Vulvar Neoplasms | 1 | 2017 | 266 | 0.470 |
Why?
|
| Hyperprolactinemia | 1 | 2015 | 124 | 0.470 |
Why?
|
| Bone and Bones | 3 | 2012 | 2590 | 0.470 |
Why?
|
| Papillomavirus Infections | 2 | 2017 | 1640 | 0.460 |
Why?
|
| Drug Costs | 2 | 2017 | 1195 | 0.460 |
Why?
|
| Immunization Programs | 1 | 2017 | 267 | 0.460 |
Why?
|
| Osteoporosis, Postmenopausal | 4 | 2017 | 399 | 0.450 |
Why?
|
| Insurance, Health | 3 | 2016 | 2517 | 0.450 |
Why?
|
| Mammary Neoplasms, Experimental | 7 | 2011 | 506 | 0.450 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2012 | 951 | 0.450 |
Why?
|
| Genes, BRCA1 | 6 | 2005 | 755 | 0.450 |
Why?
|
| Papillomaviridae | 2 | 2017 | 1140 | 0.440 |
Why?
|
| Bone Density Conservation Agents | 5 | 2017 | 797 | 0.440 |
Why?
|
| Prolactin | 1 | 2015 | 627 | 0.430 |
Why?
|
| Swainsonine | 5 | 1997 | 9 | 0.430 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2016 | 269 | 0.430 |
Why?
|
| Carcinoma | 2 | 2017 | 2332 | 0.420 |
Why?
|
| Canada | 10 | 2024 | 2130 | 0.420 |
Why?
|
| Ovariectomy | 8 | 2011 | 613 | 0.410 |
Why?
|
| Aged, 80 and over | 39 | 2020 | 59626 | 0.410 |
Why?
|
| Antineoplastic Agents, Phytogenic | 5 | 2005 | 622 | 0.410 |
Why?
|
| Women's Health Services | 1 | 2012 | 87 | 0.390 |
Why?
|
| Lymphoma, Non-Hodgkin | 6 | 1995 | 1375 | 0.390 |
Why?
|
| Cervix Uteri | 1 | 2015 | 577 | 0.390 |
Why?
|
| Clinical Trials, Phase III as Topic | 8 | 2020 | 878 | 0.390 |
Why?
|
| Methylnitrosourea | 3 | 2011 | 30 | 0.390 |
Why?
|
| Research Design | 7 | 2013 | 6209 | 0.380 |
Why?
|
| Aromatase | 5 | 2020 | 147 | 0.380 |
Why?
|
| Kaplan-Meier Estimate | 9 | 2018 | 6525 | 0.380 |
Why?
|
| Lipid Metabolism | 3 | 2011 | 1904 | 0.380 |
Why?
|
| Adult | 82 | 2021 | 223646 | 0.370 |
Why?
|
| Neoplasm Proteins | 10 | 2021 | 3604 | 0.360 |
Why?
|
| Musculoskeletal Abnormalities | 1 | 2012 | 101 | 0.360 |
Why?
|
| Lumbar Vertebrae | 6 | 2014 | 1886 | 0.360 |
Why?
|
| Femur | 5 | 2009 | 1321 | 0.350 |
Why?
|
| Radiation Injuries | 2 | 2013 | 1198 | 0.340 |
Why?
|
| Musculoskeletal Diseases | 1 | 2016 | 599 | 0.340 |
Why?
|
| Survival Analysis | 15 | 2016 | 10099 | 0.330 |
Why?
|
| Homeodomain Proteins | 4 | 2016 | 2430 | 0.320 |
Why?
|
| Protein Kinase Inhibitors | 7 | 2017 | 5704 | 0.320 |
Why?
|
| Cancer Vaccines | 1 | 2017 | 1040 | 0.320 |
Why?
|
| Tretinoin | 2 | 2011 | 525 | 0.320 |
Why?
|
| DNA, Viral | 1 | 2015 | 2204 | 0.310 |
Why?
|
| Randomized Controlled Trials as Topic | 17 | 2020 | 10397 | 0.310 |
Why?
|
| Estradiol | 14 | 2021 | 1951 | 0.310 |
Why?
|
| Patient Selection | 6 | 2021 | 4260 | 0.310 |
Why?
|
| Mastectomy | 10 | 2017 | 1862 | 0.310 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2008 | 384 | 0.310 |
Why?
|
| Prognosis | 21 | 2021 | 30009 | 0.310 |
Why?
|
| Carpal Tunnel Syndrome | 1 | 2012 | 304 | 0.300 |
Why?
|
| Neoplasms, Radiation-Induced | 3 | 2007 | 542 | 0.300 |
Why?
|
| Neoadjuvant Therapy | 8 | 2017 | 2907 | 0.280 |
Why?
|
| Polymorphism, Single Nucleotide | 12 | 2021 | 16044 | 0.280 |
Why?
|
| Recombinant Proteins | 1 | 2017 | 6512 | 0.280 |
Why?
|
| Neoplasms, Second Primary | 4 | 2008 | 1061 | 0.280 |
Why?
|
| Breast Neoplasms, Male | 3 | 2015 | 213 | 0.280 |
Why?
|
| Perimenopause | 2 | 2017 | 142 | 0.270 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 2 | 2001 | 792 | 0.270 |
Why?
|
| Carboplatin | 5 | 2021 | 797 | 0.270 |
Why?
|
| Receptors, Interleukin-17 | 5 | 2016 | 82 | 0.270 |
Why?
|
| Combined Modality Therapy | 12 | 2018 | 8542 | 0.270 |
Why?
|
| Pregnancy Outcome | 1 | 2017 | 2972 | 0.260 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2007 | 187 | 0.260 |
Why?
|
| Hodgkin Disease | 4 | 2007 | 1384 | 0.260 |
Why?
|
| Hot Flashes | 3 | 2014 | 330 | 0.250 |
Why?
|
| Flax | 1 | 2005 | 10 | 0.250 |
Why?
|
| Silencer Elements, Transcriptional | 1 | 2005 | 10 | 0.250 |
Why?
|
| Incidence | 13 | 2020 | 21538 | 0.250 |
Why?
|
| Cyclooxygenase Inhibitors | 2 | 2004 | 361 | 0.250 |
Why?
|
| Hypertrophy | 2 | 2021 | 562 | 0.240 |
Why?
|
| Testicular Neoplasms | 7 | 2000 | 806 | 0.240 |
Why?
|
| Primary Prevention | 2 | 2012 | 1188 | 0.240 |
Why?
|
| Genes, erbB-2 | 2 | 2008 | 162 | 0.240 |
Why?
|
| Promoter Regions, Genetic | 4 | 2003 | 5797 | 0.240 |
Why?
|
| Proto-Oncogene Proteins | 6 | 2018 | 4528 | 0.240 |
Why?
|
| Vaccination | 1 | 2017 | 3437 | 0.240 |
Why?
|
| Delivery of Health Care | 3 | 2021 | 5367 | 0.230 |
Why?
|
| Time Factors | 17 | 2017 | 40220 | 0.230 |
Why?
|
| Clinical Trials Data Monitoring Committees | 2 | 2018 | 25 | 0.230 |
Why?
|
| Mastectomy, Segmental | 4 | 2016 | 974 | 0.230 |
Why?
|
| Estrogen Receptor alpha | 5 | 2020 | 581 | 0.230 |
Why?
|
| Antibodies, Monoclonal | 3 | 2011 | 9262 | 0.230 |
Why?
|
| Age Factors | 12 | 2018 | 18415 | 0.230 |
Why?
|
| China | 3 | 2014 | 2395 | 0.220 |
Why?
|
| Transcription Factors | 10 | 2005 | 12171 | 0.220 |
Why?
|
| Bone Resorption | 2 | 2007 | 728 | 0.220 |
Why?
|
| Rats, Sprague-Dawley | 7 | 2011 | 8142 | 0.220 |
Why?
|
| Menopause | 12 | 2020 | 1656 | 0.220 |
Why?
|
| Progesterone | 1 | 2008 | 752 | 0.220 |
Why?
|
| Germinoma | 4 | 2000 | 132 | 0.220 |
Why?
|
| Proportional Hazards Models | 8 | 2017 | 12543 | 0.220 |
Why?
|
| Brazil | 4 | 2020 | 1250 | 0.220 |
Why?
|
| Phytotherapy | 1 | 2005 | 298 | 0.210 |
Why?
|
| Rats | 15 | 2011 | 23782 | 0.210 |
Why?
|
| Radiotherapy | 4 | 2012 | 1502 | 0.210 |
Why?
|
| Gene Expression Regulation, Neoplastic | 9 | 2021 | 8648 | 0.200 |
Why?
|
| Follow-Up Studies | 15 | 2020 | 39354 | 0.200 |
Why?
|
| Cause of Death | 2 | 2016 | 3721 | 0.200 |
Why?
|
| Antipsychotic Agents | 1 | 2015 | 3081 | 0.200 |
Why?
|
| Insurance Coverage | 1 | 2013 | 1946 | 0.200 |
Why?
|
| Bone Neoplasms | 3 | 2011 | 2565 | 0.190 |
Why?
|
| Postpartum Period | 2 | 2021 | 1197 | 0.190 |
Why?
|
| Quality of Health Care | 2 | 2016 | 4310 | 0.190 |
Why?
|
| Clinical Trials, Phase II as Topic | 4 | 2013 | 640 | 0.180 |
Why?
|
| Introns | 2 | 2001 | 965 | 0.180 |
Why?
|
| Paclitaxel | 2 | 2017 | 1733 | 0.180 |
Why?
|
| Ifosfamide | 5 | 1995 | 233 | 0.180 |
Why?
|
| Ovarian Neoplasms | 2 | 2017 | 4916 | 0.180 |
Why?
|
| Palliative Care | 4 | 2020 | 3643 | 0.180 |
Why?
|
| Dose-Response Relationship, Drug | 9 | 2015 | 10763 | 0.180 |
Why?
|
| Colombia | 1 | 2021 | 287 | 0.170 |
Why?
|
| Healthcare Disparities | 2 | 2014 | 3415 | 0.170 |
Why?
|
| Cholesterol | 3 | 2012 | 2914 | 0.170 |
Why?
|
| Estrogen Receptor Modulators | 3 | 2006 | 58 | 0.170 |
Why?
|
| Drug Resistance, Neoplasm | 8 | 2020 | 5341 | 0.160 |
Why?
|
| Survival Rate | 13 | 2007 | 12840 | 0.160 |
Why?
|
| Recurrence | 5 | 2016 | 8509 | 0.160 |
Why?
|
| Megestrol Acetate | 1 | 1999 | 18 | 0.160 |
Why?
|
| Minority Groups | 1 | 2006 | 1216 | 0.160 |
Why?
|
| BRCA1 Protein | 4 | 2021 | 1155 | 0.160 |
Why?
|
| Risk Factors | 20 | 2018 | 74944 | 0.160 |
Why?
|
| Multicenter Studies as Topic | 4 | 2020 | 1737 | 0.150 |
Why?
|
| INDEL Mutation | 1 | 2019 | 267 | 0.150 |
Why?
|
| Organ Size | 3 | 2011 | 2267 | 0.150 |
Why?
|
| Quinolines | 2 | 2014 | 772 | 0.150 |
Why?
|
| Animals | 34 | 2017 | 169285 | 0.150 |
Why?
|
| Aniline Compounds | 2 | 2014 | 1094 | 0.150 |
Why?
|
| Genes, Homeobox | 1 | 1999 | 289 | 0.150 |
Why?
|
| Bone Remodeling | 3 | 2007 | 583 | 0.150 |
Why?
|
| Transcriptional Activation | 2 | 2003 | 1750 | 0.140 |
Why?
|
| Disease Progression | 11 | 2017 | 13668 | 0.140 |
Why?
|
| Lung Neoplasms | 8 | 2018 | 13586 | 0.140 |
Why?
|
| Transcription Factor RelA | 1 | 2018 | 253 | 0.140 |
Why?
|
| Cisplatin | 6 | 2015 | 1660 | 0.140 |
Why?
|
| Prospective Studies | 16 | 2020 | 54924 | 0.130 |
Why?
|
| Etoposide | 7 | 1995 | 639 | 0.130 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2017 | 260 | 0.130 |
Why?
|
| Epirubicin | 2 | 1998 | 82 | 0.130 |
Why?
|
| Genes, p53 | 2 | 2021 | 714 | 0.130 |
Why?
|
| Secondary Prevention | 2 | 2016 | 1474 | 0.130 |
Why?
|
| Models, Genetic | 2 | 2011 | 3447 | 0.130 |
Why?
|
| Drug Screening Assays, Antitumor | 3 | 2011 | 719 | 0.130 |
Why?
|
| Acetic Acid | 1 | 2015 | 59 | 0.130 |
Why?
|
| Risk Assessment | 11 | 2018 | 24318 | 0.130 |
Why?
|
| Lymph Node Excision | 2 | 1999 | 1271 | 0.130 |
Why?
|
| Transcription, Genetic | 4 | 2018 | 7609 | 0.130 |
Why?
|
| Piperidines | 1 | 2004 | 1667 | 0.130 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2000 | 1169 | 0.130 |
Why?
|
| Alkaline Phosphatase | 2 | 2011 | 864 | 0.130 |
Why?
|
| Mental Disorders | 1 | 2015 | 6873 | 0.130 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2019 | 3670 | 0.120 |
Why?
|
| Multivariate Analysis | 4 | 2017 | 12077 | 0.120 |
Why?
|
| Collagen Type I | 2 | 2011 | 620 | 0.120 |
Why?
|
| Genital Neoplasms, Female | 1 | 2020 | 536 | 0.120 |
Why?
|
| Caribbean Region | 1 | 2015 | 193 | 0.120 |
Why?
|
| Receptors, Calcitriol | 1 | 2017 | 361 | 0.120 |
Why?
|
| Allied Health Personnel | 1 | 2016 | 156 | 0.120 |
Why?
|
| Indicators and Reagents | 1 | 2015 | 456 | 0.120 |
Why?
|
| Gene Fusion | 1 | 2017 | 356 | 0.120 |
Why?
|
| Molecular Sequence Data | 9 | 2005 | 17623 | 0.120 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1998 | 594 | 0.120 |
Why?
|
| Endometrial Neoplasms | 2 | 2018 | 1382 | 0.120 |
Why?
|
| Base Sequence | 8 | 2005 | 12422 | 0.120 |
Why?
|
| Patient Dropouts | 1 | 2017 | 411 | 0.120 |
Why?
|
| Bones of Lower Extremity | 1 | 2014 | 6 | 0.120 |
Why?
|
| Carbohydrate Metabolism | 1 | 1995 | 262 | 0.120 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2013 | 4585 | 0.120 |
Why?
|
| Fractures, Bone | 3 | 2014 | 2062 | 0.110 |
Why?
|
| Health Care Surveys | 2 | 2016 | 2434 | 0.110 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2004 | 2057 | 0.110 |
Why?
|
| Genotype | 7 | 2020 | 13045 | 0.110 |
Why?
|
| Gene Silencing | 1 | 2000 | 1505 | 0.110 |
Why?
|
| Cardiovascular Diseases | 3 | 2016 | 15662 | 0.110 |
Why?
|
| Medicine, Chinese Traditional | 1 | 2014 | 75 | 0.110 |
Why?
|
| Cohort Studies | 9 | 2021 | 41753 | 0.110 |
Why?
|
| West Indies | 1 | 2013 | 32 | 0.110 |
Why?
|
| Tumor Cells, Cultured | 7 | 2003 | 6124 | 0.110 |
Why?
|
| Lymphatic Metastasis | 6 | 2016 | 2914 | 0.110 |
Why?
|
| Arthralgia | 1 | 2017 | 459 | 0.110 |
Why?
|
| Economic Development | 1 | 2014 | 72 | 0.110 |
Why?
|
| Russia | 1 | 2014 | 386 | 0.110 |
Why?
|
| Absorptiometry, Photon | 2 | 2012 | 1758 | 0.110 |
Why?
|
| Urban Health Services | 1 | 2014 | 177 | 0.110 |
Why?
|
| Vulnerable Populations | 1 | 2018 | 718 | 0.110 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 2 | 2004 | 319 | 0.100 |
Why?
|
| Insulin-Like Growth Factor I | 3 | 2011 | 1942 | 0.100 |
Why?
|
| Receptors, Steroid | 2 | 2017 | 156 | 0.100 |
Why?
|
| DNA-Binding Proteins | 5 | 2003 | 9617 | 0.100 |
Why?
|
| Environmental Pollution | 1 | 2014 | 125 | 0.100 |
Why?
|
| Mass Screening | 4 | 2020 | 5458 | 0.100 |
Why?
|
| Disease Models, Animal | 3 | 2007 | 18349 | 0.100 |
Why?
|
| Vitamin D | 4 | 2017 | 3311 | 0.100 |
Why?
|
| Vaginal Smears | 1 | 2015 | 505 | 0.100 |
Why?
|
| Aminoglutethimide | 5 | 1986 | 13 | 0.100 |
Why?
|
| Cultural Characteristics | 1 | 2014 | 250 | 0.100 |
Why?
|
| History, 18th Century | 1 | 2013 | 206 | 0.100 |
Why?
|
| Signal Transduction | 5 | 2016 | 23648 | 0.100 |
Why?
|
| Pain | 4 | 2019 | 5099 | 0.100 |
Why?
|
| Drug Evaluation | 6 | 1997 | 642 | 0.100 |
Why?
|
| Drug Eruptions | 1 | 2015 | 335 | 0.100 |
Why?
|
| Case-Control Studies | 10 | 2020 | 22290 | 0.100 |
Why?
|
| Survival | 1 | 2012 | 160 | 0.100 |
Why?
|
| Gene Expression Regulation | 5 | 2018 | 11930 | 0.100 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2011 | 934 | 0.100 |
Why?
|
| Estrone | 3 | 2021 | 234 | 0.100 |
Why?
|
| Chi-Square Distribution | 2 | 2012 | 3436 | 0.100 |
Why?
|
| Mannosidases | 3 | 1997 | 21 | 0.100 |
Why?
|
| alpha-Mannosidase | 3 | 1997 | 19 | 0.100 |
Why?
|
| Public Sector | 1 | 2013 | 266 | 0.100 |
Why?
|
| Mental Health | 3 | 2006 | 3275 | 0.100 |
Why?
|
| Weight Gain | 2 | 2017 | 2359 | 0.100 |
Why?
|
| Review Literature as Topic | 1 | 2013 | 297 | 0.100 |
Why?
|
| Retrospective Studies | 15 | 2019 | 81760 | 0.100 |
Why?
|
| Interleukin-1beta | 1 | 2017 | 1028 | 0.090 |
Why?
|
| Genome-Wide Association Study | 9 | 2021 | 12795 | 0.090 |
Why?
|
| Chemokines | 1 | 2016 | 963 | 0.090 |
Why?
|
| Cyclooxygenase 2 | 2 | 2004 | 598 | 0.090 |
Why?
|
| BRCA2 Protein | 5 | 2015 | 802 | 0.090 |
Why?
|
| Health Resources | 1 | 2017 | 950 | 0.090 |
Why?
|
| Administration, Oral | 6 | 2005 | 4034 | 0.090 |
Why?
|
| Comorbidity | 4 | 2016 | 10590 | 0.090 |
Why?
|
| NF-kappa B | 2 | 2017 | 2494 | 0.090 |
Why?
|
| Health Services Research | 1 | 2018 | 1815 | 0.090 |
Why?
|
| Isoenzymes | 3 | 2004 | 1688 | 0.090 |
Why?
|
| Sleep Disorders, Intrinsic | 1 | 2010 | 16 | 0.090 |
Why?
|
| Sarcoma, Kaposi | 2 | 1991 | 376 | 0.090 |
Why?
|
| Glycoproteins | 2 | 1995 | 2202 | 0.090 |
Why?
|
| Membrane Proteins | 3 | 2020 | 7876 | 0.090 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 3 | 2007 | 354 | 0.090 |
Why?
|
| Medroxyprogesterone | 2 | 1989 | 34 | 0.090 |
Why?
|
| Tetrahydronaphthalenes | 1 | 2010 | 85 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2021 | 18065 | 0.090 |
Why?
|
| Private Sector | 1 | 2013 | 396 | 0.090 |
Why?
|
| Tumor Burden | 2 | 2018 | 1906 | 0.090 |
Why?
|
| Postoperative Complications | 1 | 2013 | 15833 | 0.090 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2020 | 2810 | 0.090 |
Why?
|
| Rural Health Services | 1 | 2014 | 394 | 0.090 |
Why?
|
| Femur Neck | 1 | 2012 | 318 | 0.090 |
Why?
|
| Cyclohexanols | 1 | 2010 | 126 | 0.090 |
Why?
|
| Delayed Diagnosis | 1 | 2014 | 467 | 0.090 |
Why?
|
| Lymphoma | 1 | 1999 | 1898 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2010 | 286 | 0.080 |
Why?
|
| HLA Antigens | 1 | 2015 | 1334 | 0.080 |
Why?
|
| Dietary Supplements | 2 | 2014 | 3445 | 0.080 |
Why?
|
| Salvage Therapy | 2 | 1995 | 1273 | 0.080 |
Why?
|
| Health Care Costs | 2 | 2013 | 3239 | 0.080 |
Why?
|
| Calcium | 2 | 2014 | 5792 | 0.080 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2016 | 2521 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 2 | 2019 | 7454 | 0.080 |
Why?
|
| Models, Organizational | 1 | 2013 | 548 | 0.080 |
Why?
|
| Octreotide | 3 | 2016 | 156 | 0.080 |
Why?
|
| Minor Histocompatibility Antigens | 2 | 2021 | 303 | 0.080 |
Why?
|
| Osteoporotic Fractures | 1 | 2014 | 417 | 0.080 |
Why?
|
| Needs Assessment | 1 | 2015 | 1141 | 0.080 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2007 | 1628 | 0.080 |
Why?
|
| Cost-Benefit Analysis | 2 | 2017 | 5536 | 0.080 |
Why?
|
| Cell Size | 1 | 2011 | 626 | 0.080 |
Why?
|
| Socioeconomic Factors | 2 | 2014 | 7852 | 0.080 |
Why?
|
| Male | 37 | 2019 | 364731 | 0.080 |
Why?
|
| Health Services Needs and Demand | 1 | 2017 | 1406 | 0.080 |
Why?
|
| Mitoxantrone | 4 | 2000 | 148 | 0.080 |
Why?
|
| Long-Term Care | 1 | 2013 | 631 | 0.080 |
Why?
|
| Repressor Proteins | 1 | 2000 | 2982 | 0.080 |
Why?
|
| Social Support | 1 | 2019 | 2193 | 0.080 |
Why?
|
| Antigens, Neoplasm | 1 | 2017 | 1996 | 0.080 |
Why?
|
| Health Services | 1 | 2014 | 755 | 0.080 |
Why?
|
| Oligosaccharides | 3 | 1997 | 407 | 0.080 |
Why?
|
| Antibodies | 1 | 2017 | 2421 | 0.080 |
Why?
|
| Pyrrolidines | 1 | 2010 | 341 | 0.080 |
Why?
|
| Doxorubicin | 4 | 2000 | 2234 | 0.080 |
Why?
|
| Survivors | 2 | 2010 | 2381 | 0.080 |
Why?
|
| Inflammation Mediators | 1 | 2017 | 1892 | 0.080 |
Why?
|
| Compressive Strength | 1 | 2009 | 159 | 0.080 |
Why?
|
| Biopsy | 4 | 2017 | 6792 | 0.080 |
Why?
|
| Response Elements | 3 | 2018 | 308 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 3 | 2011 | 3620 | 0.070 |
Why?
|
| Mutation | 9 | 2021 | 30237 | 0.070 |
Why?
|
| Preventive Health Services | 1 | 2012 | 570 | 0.070 |
Why?
|
| Gene Expression | 2 | 1999 | 7601 | 0.070 |
Why?
|
| Social Stigma | 1 | 2014 | 788 | 0.070 |
Why?
|
| India | 1 | 2014 | 2334 | 0.070 |
Why?
|
| Vinblastine | 2 | 2000 | 487 | 0.070 |
Why?
|
| Chromatography, Thin Layer | 3 | 2005 | 212 | 0.070 |
Why?
|
| Poverty | 1 | 2018 | 2720 | 0.070 |
Why?
|
| Data Mining | 1 | 2011 | 563 | 0.070 |
Why?
|
| Peptides | 2 | 2011 | 4354 | 0.070 |
Why?
|
| Pregnancy | 3 | 2021 | 30255 | 0.070 |
Why?
|
| Pilot Projects | 3 | 2006 | 8741 | 0.070 |
Why?
|
| Risk | 3 | 2013 | 9613 | 0.070 |
Why?
|
| Membrane Glycoproteins | 1 | 2017 | 3713 | 0.070 |
Why?
|
| Procollagen | 1 | 2007 | 189 | 0.070 |
Why?
|
| Sulfonamides | 2 | 2008 | 1982 | 0.070 |
Why?
|
| Alleles | 2 | 2015 | 6894 | 0.070 |
Why?
|
| Chemoprevention | 2 | 2020 | 327 | 0.070 |
Why?
|
| Medication Adherence | 1 | 2018 | 2187 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2013 | 15453 | 0.060 |
Why?
|
| Injections, Intramuscular | 4 | 2004 | 556 | 0.060 |
Why?
|
| Hypercholesterolemia | 1 | 2013 | 1145 | 0.060 |
Why?
|
| Apoptosis | 3 | 2011 | 9527 | 0.060 |
Why?
|
| Goserelin | 1 | 2006 | 126 | 0.060 |
Why?
|
| Referral and Consultation | 1 | 2018 | 3620 | 0.060 |
Why?
|
| Pyrazoles | 2 | 2008 | 2028 | 0.060 |
Why?
|
| Drug Therapy, Combination | 3 | 2010 | 6316 | 0.060 |
Why?
|
| Ontario | 3 | 2006 | 403 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 5 | 2 | 1999 | 387 | 0.060 |
Why?
|
| Cholesterol, LDL | 2 | 2005 | 2403 | 0.060 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 1991 | 2204 | 0.060 |
Why?
|
| Data Collection | 1 | 2014 | 3326 | 0.060 |
Why?
|
| Hip Joint | 1 | 2012 | 1018 | 0.060 |
Why?
|
| Carcinoma, Small Cell | 3 | 1992 | 419 | 0.060 |
Why?
|
| Lymph Nodes | 2 | 2016 | 3474 | 0.060 |
Why?
|
| Bile | 1 | 1986 | 299 | 0.060 |
Why?
|
| Vascular Diseases | 1 | 2013 | 1162 | 0.060 |
Why?
|
| Adolescent | 7 | 2020 | 89169 | 0.060 |
Why?
|
| Lignans | 1 | 2005 | 84 | 0.060 |
Why?
|
| Gastrointestinal Diseases | 1 | 2013 | 1205 | 0.060 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2005 | 294 | 0.060 |
Why?
|
| Models, Chemical | 1 | 2006 | 611 | 0.060 |
Why?
|
| Health Policy | 1 | 2017 | 2697 | 0.060 |
Why?
|
| Treatment Failure | 2 | 2002 | 2661 | 0.060 |
Why?
|
| Cell Line, Tumor | 5 | 2017 | 17142 | 0.060 |
Why?
|
| Osteocalcin | 1 | 2004 | 277 | 0.060 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2017 | 1791 | 0.060 |
Why?
|
| Sequence Deletion | 2 | 2000 | 1497 | 0.060 |
Why?
|
| Sample Size | 1 | 2007 | 846 | 0.060 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2010 | 952 | 0.060 |
Why?
|
| Health Care Reform | 1 | 2013 | 1256 | 0.060 |
Why?
|
| Stress, Mechanical | 1 | 2009 | 1680 | 0.050 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 1998 | 681 | 0.050 |
Why?
|
| Neutropenia | 5 | 2000 | 892 | 0.050 |
Why?
|
| Binding Sites | 3 | 2003 | 6019 | 0.050 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 2830 | 0.050 |
Why?
|
| Cholesterol, HDL | 2 | 2012 | 1820 | 0.050 |
Why?
|
| Young Adult | 3 | 2015 | 60066 | 0.050 |
Why?
|
| Analgesics, Opioid | 1 | 2019 | 3837 | 0.050 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 2271 | 0.050 |
Why?
|
| Nuclear Proteins | 3 | 2005 | 5804 | 0.050 |
Why?
|
| Alcoholism | 1 | 2014 | 1980 | 0.050 |
Why?
|
| Remission Induction | 4 | 1994 | 2410 | 0.050 |
Why?
|
| Genes, Tumor Suppressor | 2 | 1999 | 1062 | 0.050 |
Why?
|
| Ki-67 Antigen | 1 | 2005 | 630 | 0.050 |
Why?
|
| Single-Blind Method | 1 | 2007 | 1587 | 0.050 |
Why?
|
| Radiography | 1 | 2014 | 6986 | 0.050 |
Why?
|
| Gene Expression Profiling | 3 | 2015 | 9540 | 0.050 |
Why?
|
| Protein Binding | 3 | 2016 | 9343 | 0.050 |
Why?
|
| Hypnotics and Sedatives | 1 | 2010 | 1191 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2014 | 20225 | 0.050 |
Why?
|
| Cell Line | 7 | 2018 | 15602 | 0.050 |
Why?
|
| Markov Chains | 1 | 2006 | 979 | 0.050 |
Why?
|
| Heterozygote | 4 | 2015 | 2798 | 0.050 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2017 | 905 | 0.050 |
Why?
|
| Patient Compliance | 2 | 2017 | 2697 | 0.050 |
Why?
|
| Oligonucleotides | 1 | 2005 | 563 | 0.050 |
Why?
|
| Residence Characteristics | 1 | 2012 | 2118 | 0.050 |
Why?
|
| Immunohistochemistry | 3 | 2013 | 11095 | 0.050 |
Why?
|
| Health Status Disparities | 1 | 2013 | 1885 | 0.050 |
Why?
|
| Probability | 2 | 2005 | 2479 | 0.050 |
Why?
|
| Hormone Replacement Therapy | 1 | 2007 | 757 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 2 | 2019 | 4786 | 0.050 |
Why?
|
| Biomedical Research | 1 | 2017 | 3463 | 0.050 |
Why?
|
| Logistic Models | 2 | 2013 | 13290 | 0.050 |
Why?
|
| Cross-Over Studies | 1 | 2007 | 2107 | 0.050 |
Why?
|
| Body Mass Index | 2 | 2017 | 13053 | 0.050 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2003 | 2846 | 0.050 |
Why?
|
| United States | 5 | 2014 | 73039 | 0.050 |
Why?
|
| Immunotherapy | 1 | 2017 | 4754 | 0.050 |
Why?
|
| Dinoprostone | 1 | 2004 | 597 | 0.050 |
Why?
|
| Jews | 2 | 1999 | 359 | 0.050 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2007 | 1197 | 0.040 |
Why?
|
| Blood-Brain Barrier | 1 | 2007 | 1035 | 0.040 |
Why?
|
| Drug Tolerance | 1 | 2002 | 365 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2021 | 2956 | 0.040 |
Why?
|
| Protein Kinases | 1 | 2007 | 1611 | 0.040 |
Why?
|
| Immunity, Cellular | 2 | 2017 | 1561 | 0.040 |
Why?
|
| Clinical Trials, Phase IV as Topic | 1 | 2020 | 30 | 0.040 |
Why?
|
| Neoplastic Stem Cells | 1 | 2008 | 1351 | 0.040 |
Why?
|
| Epithelial Cells | 2 | 2010 | 3703 | 0.040 |
Why?
|
| Progestins | 1 | 2002 | 302 | 0.040 |
Why?
|
| Molecular Structure | 1 | 2004 | 1884 | 0.040 |
Why?
|
| Prednisone | 2 | 1995 | 1567 | 0.040 |
Why?
|
| Glucuronosyltransferase | 1 | 2020 | 136 | 0.040 |
Why?
|
| Nomograms | 1 | 2021 | 236 | 0.040 |
Why?
|
| Plasmids | 1 | 2005 | 2269 | 0.040 |
Why?
|
| Carbohydrate Sequence | 2 | 1997 | 411 | 0.040 |
Why?
|
| Population Surveillance | 2 | 2007 | 2596 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2003 | 1760 | 0.040 |
Why?
|
| Steroids | 1 | 2004 | 938 | 0.040 |
Why?
|
| POU Domain Factors | 1 | 1999 | 47 | 0.040 |
Why?
|
| Consensus Sequence | 1 | 1999 | 363 | 0.040 |
Why?
|
| Cushing Syndrome | 2 | 1992 | 241 | 0.040 |
Why?
|
| Cell Survival | 2 | 2007 | 5789 | 0.040 |
Why?
|
| Models, Biological | 2 | 2006 | 9497 | 0.040 |
Why?
|
| Caco-2 Cells | 1 | 1999 | 367 | 0.040 |
Why?
|
| Oncogene Proteins | 1 | 2003 | 717 | 0.040 |
Why?
|
| Palpation | 1 | 1999 | 166 | 0.040 |
Why?
|
| Edema | 2 | 1997 | 765 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2021 | 10478 | 0.040 |
Why?
|
| Pyridines | 1 | 2010 | 2894 | 0.040 |
Why?
|
| DNA | 4 | 2015 | 7213 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2003 | 1623 | 0.040 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2007 | 2062 | 0.040 |
Why?
|
| Cyclins | 1 | 2000 | 606 | 0.040 |
Why?
|
| DNA Primers | 2 | 2000 | 2828 | 0.040 |
Why?
|
| Pedigree | 3 | 1997 | 4539 | 0.040 |
Why?
|
| Amino Acids | 1 | 2004 | 1716 | 0.040 |
Why?
|
| Body Weight | 1 | 2009 | 4627 | 0.040 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1999 | 1057 | 0.040 |
Why?
|
| Fluorouracil | 3 | 2000 | 1652 | 0.040 |
Why?
|
| Lectins, C-Type | 1 | 2021 | 594 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2019 | 452 | 0.040 |
Why?
|
| Verapamil | 1 | 1998 | 242 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2013 | 3857 | 0.040 |
Why?
|
| Fibroblast Growth Factors | 1 | 2003 | 873 | 0.040 |
Why?
|
| DNA Repair | 2 | 1998 | 2050 | 0.040 |
Why?
|
| Carcinoembryonic Antigen | 1 | 1999 | 338 | 0.040 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2017 | 203 | 0.040 |
Why?
|
| Blotting, Western | 3 | 2003 | 5028 | 0.040 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 5891 | 0.040 |
Why?
|
| Carbohydrate Conformation | 1 | 1997 | 206 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2017 | 205 | 0.040 |
Why?
|
| Data Interpretation, Statistical | 1 | 2007 | 2709 | 0.030 |
Why?
|
| Smoking | 1 | 2014 | 9092 | 0.030 |
Why?
|
| Retinoblastoma Protein | 1 | 2000 | 671 | 0.030 |
Why?
|
| DNA, Neoplasm | 3 | 1997 | 1744 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2017 | 36741 | 0.030 |
Why?
|
| Lymphocytes | 2 | 2016 | 2614 | 0.030 |
Why?
|
| Loss of Heterozygosity | 2 | 2015 | 663 | 0.030 |
Why?
|
| Cytokines | 1 | 2012 | 7452 | 0.030 |
Why?
|
| Risk Management | 1 | 2000 | 558 | 0.030 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1999 | 1730 | 0.030 |
Why?
|
| Cloning, Molecular | 2 | 2000 | 4168 | 0.030 |
Why?
|
| Physicians | 1 | 2014 | 4598 | 0.030 |
Why?
|
| Fatigue | 1 | 2003 | 1557 | 0.030 |
Why?
|
| X Chromosome | 1 | 2000 | 819 | 0.030 |
Why?
|
| Infusions, Intravenous | 3 | 2000 | 2230 | 0.030 |
Why?
|
| Pharmacogenetics | 1 | 2020 | 683 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2021 | 757 | 0.030 |
Why?
|
| Coronary Artery Disease | 1 | 2016 | 6568 | 0.030 |
Why?
|
| Sex Hormone-Binding Globulin | 2 | 2010 | 553 | 0.030 |
Why?
|
| Axilla | 1 | 1999 | 623 | 0.030 |
Why?
|
| Benzimidazoles | 1 | 2021 | 864 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 2000 | 1524 | 0.030 |
Why?
|
| Transfection | 2 | 2003 | 5756 | 0.030 |
Why?
|
| Trinucleotide Repeats | 1 | 1997 | 257 | 0.030 |
Why?
|
| Hypertension | 1 | 2016 | 8616 | 0.030 |
Why?
|
| Bleomycin | 1 | 1996 | 493 | 0.030 |
Why?
|
| Aspartate Aminotransferases | 1 | 1997 | 414 | 0.030 |
Why?
|
| Immunity | 1 | 2021 | 1003 | 0.030 |
Why?
|
| Dexamethasone | 2 | 1995 | 1965 | 0.030 |
Why?
|
| Polymorphism, Genetic | 2 | 2016 | 4249 | 0.030 |
Why?
|
| Cardiac Tamponade | 1 | 1996 | 175 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 1999 | 2300 | 0.030 |
Why?
|
| Proteins | 2 | 2001 | 6009 | 0.030 |
Why?
|
| Glycosylation | 2 | 1995 | 1100 | 0.030 |
Why?
|
| Melphalan | 1 | 1977 | 421 | 0.030 |
Why?
|
| Pyrimidinones | 1 | 2017 | 386 | 0.030 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2017 | 296 | 0.030 |
Why?
|
| Life Style | 1 | 2006 | 3932 | 0.030 |
Why?
|
| Vagina | 1 | 2020 | 850 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1999 | 2748 | 0.030 |
Why?
|
| Gonadal Steroid Hormones | 1 | 1999 | 707 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2008 | 3833 | 0.030 |
Why?
|
| Pericardial Effusion | 1 | 1996 | 246 | 0.030 |
Why?
|
| Doxycycline | 1 | 1996 | 349 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 1997 | 1379 | 0.030 |
Why?
|
| Structure-Activity Relationship | 2 | 2003 | 3056 | 0.030 |
Why?
|
| Chromosome Deletion | 1 | 1999 | 1385 | 0.030 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2001 | 1209 | 0.030 |
Why?
|
| Luteinizing Hormone | 2 | 1995 | 822 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2007 | 5151 | 0.030 |
Why?
|
| Colorectal Neoplasms | 1 | 2014 | 6975 | 0.030 |
Why?
|
| Pulmonary Embolism | 1 | 2007 | 2599 | 0.030 |
Why?
|
| HeLa Cells | 2 | 1999 | 3074 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2008 | 3231 | 0.030 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 1995 | 330 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2011 | 6395 | 0.030 |
Why?
|
| Genome, Human | 2 | 2021 | 4446 | 0.030 |
Why?
|
| Mice, Nude | 2 | 2017 | 3623 | 0.030 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2021 | 1247 | 0.030 |
Why?
|
| Hematopoietic Cell Growth Factors | 1 | 1993 | 98 | 0.030 |
Why?
|
| Heart Diseases | 1 | 2006 | 2819 | 0.030 |
Why?
|
| DNA Replication | 1 | 2000 | 1427 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2021 | 2934 | 0.030 |
Why?
|
| Haplotypes | 1 | 2019 | 2722 | 0.030 |
Why?
|
| Seminoma | 1 | 1994 | 136 | 0.030 |
Why?
|
| Diclofenac | 1 | 2013 | 69 | 0.030 |
Why?
|
| Safety | 1 | 1997 | 1159 | 0.030 |
Why?
|
| Naproxen | 1 | 2013 | 101 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2021 | 1885 | 0.030 |
Why?
|
| Follicle Stimulating Hormone | 1 | 1995 | 727 | 0.030 |
Why?
|
| Receptors, Interleukin-1 Type II | 1 | 2012 | 11 | 0.030 |
Why?
|
| Receptors, Interleukin-12 | 1 | 2012 | 26 | 0.030 |
Why?
|
| Gene Frequency | 2 | 2015 | 3623 | 0.030 |
Why?
|
| Golgi Apparatus | 1 | 1994 | 406 | 0.020 |
Why?
|
| Pyridones | 1 | 2017 | 819 | 0.020 |
Why?
|
| ACTH Syndrome, Ectopic | 1 | 1992 | 30 | 0.020 |
Why?
|
| Gene Deletion | 2 | 2000 | 2674 | 0.020 |
Why?
|
| Range of Motion, Articular | 1 | 1999 | 1597 | 0.020 |
Why?
|
| Amino Acid Sequence | 3 | 1999 | 13422 | 0.020 |
Why?
|
| Shoulder Joint | 1 | 1999 | 746 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2004 | 3706 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 2021 | 2819 | 0.020 |
Why?
|
| Liver Neoplasms | 2 | 2006 | 4363 | 0.020 |
Why?
|
| Ibuprofen | 1 | 2013 | 229 | 0.020 |
Why?
|
| Chromosome Mapping | 3 | 2010 | 4620 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2000 | 5717 | 0.020 |
Why?
|
| Medical Oncology | 1 | 2003 | 2346 | 0.020 |
Why?
|
| Family Health | 2 | 1999 | 1255 | 0.020 |
Why?
|
| Skin Diseases | 1 | 2000 | 1085 | 0.020 |
Why?
|
| Mediastinal Neoplasms | 1 | 1994 | 403 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 1998 | 1793 | 0.020 |
Why?
|
| Ultraviolet Rays | 1 | 1976 | 1103 | 0.020 |
Why?
|
| Point Mutation | 1 | 1996 | 1596 | 0.020 |
Why?
|
| Genomic Instability | 1 | 2015 | 716 | 0.020 |
Why?
|
| Mice | 8 | 2003 | 82049 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2021 | 4035 | 0.020 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 1994 | 335 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2013 | 1703 | 0.020 |
Why?
|
| DNA Damage | 1 | 2000 | 2469 | 0.020 |
Why?
|
| Drug Design | 1 | 1995 | 1046 | 0.020 |
Why?
|
| Hot Temperature | 1 | 1977 | 1440 | 0.020 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 1995 | 498 | 0.020 |
Why?
|
| Aldosterone | 1 | 1995 | 881 | 0.020 |
Why?
|
| Stroke | 2 | 2013 | 9755 | 0.020 |
Why?
|
| Antigens, Surface | 1 | 1994 | 1617 | 0.020 |
Why?
|
| C-Peptide | 1 | 2011 | 443 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2012 | 20762 | 0.020 |
Why?
|
| Cognition Disorders | 1 | 2003 | 3980 | 0.020 |
Why?
|
| North America | 1 | 1993 | 1289 | 0.020 |
Why?
|
| Medroxyprogesterone Acetate | 2 | 1989 | 155 | 0.020 |
Why?
|
| Interleukin-12 | 1 | 2012 | 577 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2017 | 3612 | 0.020 |
Why?
|
| Regression Analysis | 1 | 1999 | 6340 | 0.020 |
Why?
|
| Hydrocortisone | 2 | 1995 | 1841 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2017 | 2459 | 0.020 |
Why?
|
| Cyclophosphamide | 3 | 2000 | 2227 | 0.020 |
Why?
|
| Ribonucleoside Diphosphate Reductase | 1 | 2008 | 31 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 3948 | 0.020 |
Why?
|
| Pain, Postoperative | 1 | 1999 | 1765 | 0.020 |
Why?
|
| Rats, Inbred Strains | 2 | 1986 | 2087 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 2 | 1997 | 6082 | 0.020 |
Why?
|
| Bone Marrow Transplantation | 1 | 1996 | 2709 | 0.020 |
Why?
|
| Lipoprotein(a) | 1 | 2012 | 489 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2021 | 42669 | 0.020 |
Why?
|
| Blood Vessels | 1 | 2013 | 1110 | 0.020 |
Why?
|
| Androgens | 1 | 1995 | 1281 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2000 | 4939 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2012 | 1606 | 0.020 |
Why?
|
| Gastrointestinal Tract | 1 | 2013 | 840 | 0.020 |
Why?
|
| Diet | 1 | 2005 | 8089 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2011 | 1997 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 2007 | 863 | 0.020 |
Why?
|
| Genes, Neoplasm | 1 | 2008 | 371 | 0.020 |
Why?
|
| Algorithms | 1 | 2006 | 14164 | 0.020 |
Why?
|
| Interleukin-17 | 1 | 2012 | 924 | 0.020 |
Why?
|
| Autoradiography | 2 | 1997 | 728 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2015 | 2885 | 0.020 |
Why?
|
| Central Nervous System Neoplasms | 1 | 1994 | 928 | 0.020 |
Why?
|
| Ultrasonography, Mammary | 1 | 2007 | 243 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 2000 | 4978 | 0.020 |
Why?
|
| Dehydroepiandrosterone | 1 | 1986 | 259 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2000 | 4530 | 0.010 |
Why?
|
| Stromal Cells | 1 | 2010 | 1337 | 0.010 |
Why?
|
| Colorimetry | 1 | 1985 | 151 | 0.010 |
Why?
|
| Biological Availability | 1 | 2005 | 391 | 0.010 |
Why?
|
| Biological Assay | 1 | 2007 | 628 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 1993 | 2433 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 1985 | 1535 | 0.010 |
Why?
|
| Fibroblast Growth Factor 4 | 1 | 2003 | 28 | 0.010 |
Why?
|
| Bone Marrow | 2 | 1992 | 2935 | 0.010 |
Why?
|
| Odds Ratio | 2 | 2010 | 9669 | 0.010 |
Why?
|
| Autoantigens | 1 | 2008 | 890 | 0.010 |
Why?
|
| Melanoma | 3 | 1977 | 5706 | 0.010 |
Why?
|
| Women's Health | 1 | 2013 | 2082 | 0.010 |
Why?
|
| Adipocytes | 1 | 2010 | 1199 | 0.010 |
Why?
|
| Thymidine Kinase | 1 | 2003 | 286 | 0.010 |
Why?
|
| Retinal Dehydrogenase | 1 | 2003 | 78 | 0.010 |
Why?
|
| Respiration Disorders | 1 | 1986 | 364 | 0.010 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2008 | 724 | 0.010 |
Why?
|
| Head and Neck Neoplasms | 1 | 1997 | 2931 | 0.010 |
Why?
|
| Patient Advocacy | 1 | 2005 | 362 | 0.010 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2003 | 221 | 0.010 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2003 | 146 | 0.010 |
Why?
|
| Endpoint Determination | 1 | 2005 | 592 | 0.010 |
Why?
|
| Child | 2 | 2021 | 80917 | 0.010 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 1992 | 5432 | 0.010 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 2003 | 168 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 2003 | 866 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 2003 | 1084 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2010 | 4149 | 0.010 |
Why?
|
| Retinoblastoma-Binding Protein 1 | 1 | 2000 | 138 | 0.010 |
Why?
|
| Transcription Factor DP1 | 1 | 2000 | 136 | 0.010 |
Why?
|
| Age of Onset | 2 | 1999 | 3346 | 0.010 |
Why?
|
| E2F1 Transcription Factor | 1 | 2000 | 182 | 0.010 |
Why?
|
| Polyploidy | 1 | 2000 | 120 | 0.010 |
Why?
|
| E2F Transcription Factors | 1 | 2000 | 270 | 0.010 |
Why?
|
| Embryonic and Fetal Development | 1 | 2000 | 420 | 0.010 |
Why?
|
| District of Columbia | 1 | 1999 | 159 | 0.010 |
Why?
|
| Bone Diseases, Developmental | 1 | 2000 | 132 | 0.010 |
Why?
|
| Temperature | 2 | 1977 | 2234 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2003 | 1683 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2000 | 379 | 0.010 |
Why?
|
| Histocytochemistry | 1 | 2000 | 699 | 0.010 |
Why?
|
| Lod Score | 1 | 2000 | 600 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2005 | 2862 | 0.010 |
Why?
|
| Founder Effect | 1 | 1999 | 185 | 0.010 |
Why?
|
| Coronary Disease | 1 | 2013 | 5919 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1999 | 849 | 0.010 |
Why?
|
| Informed Consent | 1 | 2005 | 1010 | 0.010 |
Why?
|
| T-Lymphocytes | 2 | 1993 | 10266 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 1996 | 7477 | 0.010 |
Why?
|
| Reference Values | 1 | 2005 | 4939 | 0.010 |
Why?
|
| Software | 1 | 2011 | 4480 | 0.010 |
Why?
|
| Inflammation | 1 | 2017 | 10873 | 0.010 |
Why?
|
| Atrial Fibrillation | 1 | 1996 | 5176 | 0.010 |
Why?
|
| Family | 2 | 2000 | 3209 | 0.010 |
Why?
|
| Drug Resistance, Multiple | 1 | 1998 | 255 | 0.010 |
Why?
|
| Microsatellite Repeats | 1 | 1999 | 785 | 0.010 |
Why?
|
| Insulin | 1 | 2011 | 6610 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2000 | 1904 | 0.010 |
Why?
|
| Oligonucleotide Probes | 1 | 1997 | 417 | 0.010 |
Why?
|
| Radiation Effects | 1 | 1976 | 73 | 0.010 |
Why?
|
| Cardiography, Impedance | 1 | 1996 | 40 | 0.010 |
Why?
|
| Sclerosis | 1 | 1996 | 211 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2003 | 2939 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 1996 | 325 | 0.010 |
Why?
|
| Thymine | 1 | 1976 | 69 | 0.010 |
Why?
|
| Fibroblasts | 2 | 1977 | 4178 | 0.010 |
Why?
|
| Half-Life | 2 | 1987 | 651 | 0.010 |
Why?
|
| Cytosine | 1 | 1997 | 213 | 0.010 |
Why?
|
| Guanine | 1 | 1997 | 280 | 0.010 |
Why?
|
| Neck | 1 | 2000 | 736 | 0.010 |
Why?
|
| Bone Marrow Neoplasms | 1 | 1996 | 101 | 0.010 |
Why?
|
| France | 1 | 1996 | 497 | 0.010 |
Why?
|
| Kinetics | 3 | 1987 | 6330 | 0.010 |
Why?
|
| Codon | 1 | 1996 | 599 | 0.010 |
Why?
|
| Chromatography, Gas | 1 | 1994 | 150 | 0.010 |
Why?
|
| Cell Differentiation | 2 | 2003 | 11677 | 0.010 |
Why?
|
| Aging | 1 | 1993 | 8743 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2003 | 6231 | 0.010 |
Why?
|
| Orchiectomy | 1 | 1996 | 466 | 0.010 |
Why?
|
| Genetic Markers | 1 | 2000 | 2603 | 0.010 |
Why?
|
| RNA Viruses | 1 | 1974 | 112 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 1993 | 775 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2010 | 15949 | 0.010 |
Why?
|
| Health Status | 1 | 2005 | 4091 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2003 | 5902 | 0.010 |
Why?
|
| Thrombocytopenia | 1 | 2000 | 1179 | 0.010 |
Why?
|
| Myocardial Infarction | 1 | 2013 | 11519 | 0.010 |
Why?
|
| Agranulocytosis | 1 | 1992 | 98 | 0.010 |
Why?
|
| Ketoconazole | 1 | 1992 | 95 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2007 | 14729 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1993 | 1553 | 0.010 |
Why?
|
| Ovary | 2 | 1986 | 965 | 0.010 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1977 | 1339 | 0.010 |
Why?
|
| Acetylation | 1 | 1994 | 1056 | 0.010 |
Why?
|
| Decision Making | 1 | 2005 | 3953 | 0.010 |
Why?
|
| RNA, Messenger | 2 | 2000 | 12801 | 0.010 |
Why?
|
| Adenine | 1 | 1997 | 995 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 2003 | 7140 | 0.010 |
Why?
|
| Melanoma, Experimental | 1 | 1994 | 559 | 0.010 |
Why?
|
| Exons | 1 | 1996 | 2394 | 0.010 |
Why?
|
| Liver | 1 | 1986 | 7578 | 0.010 |
Why?
|
| Pro-Opiomelanocortin | 1 | 1989 | 138 | 0.010 |
Why?
|
| Radiography, Thoracic | 1 | 1996 | 1321 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2000 | 3445 | 0.010 |
Why?
|
| Vomiting | 1 | 1992 | 655 | 0.000 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1992 | 892 | 0.000 |
Why?
|
| Mass Spectrometry | 2 | 1986 | 2202 | 0.000 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 1989 | 619 | 0.000 |
Why?
|
| DNA Mutational Analysis | 1 | 1996 | 4120 | 0.000 |
Why?
|
| Pituitary Gland | 1 | 1989 | 634 | 0.000 |
Why?
|
| Opportunistic Infections | 1 | 1989 | 375 | 0.000 |
Why?
|
| Danazol | 1 | 1986 | 44 | 0.000 |
Why?
|
| Dihydrotestosterone | 1 | 1986 | 195 | 0.000 |
Why?
|
| Protein Processing, Post-Translational | 1 | 1994 | 1966 | 0.000 |
Why?
|
| Interferon Type I | 1 | 1989 | 569 | 0.000 |
Why?
|
| Leukemia | 1 | 1994 | 1519 | 0.000 |
Why?
|
| Mice, Knockout | 1 | 2000 | 14488 | 0.000 |
Why?
|
| Castration | 1 | 1984 | 149 | 0.000 |
Why?
|
| Cells, Cultured | 2 | 1977 | 19025 | 0.000 |
Why?
|
| Biotransformation | 1 | 1983 | 166 | 0.000 |
Why?
|
| Hemoglobins | 1 | 1989 | 1531 | 0.000 |
Why?
|
| Enzyme Induction | 1 | 1983 | 455 | 0.000 |
Why?
|
| Rabbits | 1 | 1986 | 4773 | 0.000 |
Why?
|
| Macaca mulatta | 1 | 1986 | 2363 | 0.000 |
Why?
|
| Pancreatic Neoplasms | 1 | 1996 | 5442 | 0.000 |
Why?
|
| Rauscher Virus | 1 | 1974 | 13 | 0.000 |
Why?
|
| Friend murine leukemia virus | 1 | 1974 | 37 | 0.000 |
Why?
|
| Carcinoma, Renal Cell | 1 | 1989 | 3187 | 0.000 |
Why?
|
| Centrifugation, Density Gradient | 1 | 1974 | 298 | 0.000 |
Why?
|
| Thymidine | 1 | 1974 | 297 | 0.000 |
Why?
|
| Uridine | 1 | 1974 | 135 | 0.000 |
Why?
|
| Tritium | 1 | 1974 | 707 | 0.000 |
Why?
|
| DNA Nucleotidyltransferases | 1 | 1974 | 177 | 0.000 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 1974 | 223 | 0.000 |
Why?
|
| Kidney Neoplasms | 1 | 1989 | 4282 | 0.000 |
Why?
|
| Inclusion Bodies | 1 | 1974 | 278 | 0.000 |
Why?
|
| Microscopy, Electron | 1 | 1974 | 2560 | 0.000 |
Why?
|
| Cerebellar Neoplasms | 1 | 1974 | 591 | 0.000 |
Why?
|
| Spleen | 1 | 1974 | 2296 | 0.000 |
Why?
|
| RNA, Viral | 1 | 1974 | 2874 | 0.000 |
Why?
|